Share Your Experience with the 2025 RSV Maternal & Infant Protection Program
The Vaccinology and Immunology Research Trials Unit at the Women’s and Children’s Hospital is conducting an SA Health-funded evaluation of South Australia’s RSV Maternal & Infant Protection Program (2025). We are seeking input from GPs, practice nurses, and primary care teams who provided care to pregnant women or infants during the 2025 RSV season.
Your insights are essential to understanding how the maternal RSV vaccine and infant Nirsevimab were communicated, offered, and delivered in primary care, and how coordination worked across antenatal, hospital, pharmacy, and community settings. This includes identifying what worked well, where processes were unclear or challenging, and what could be improved for 2026.
Participants will be invited to a 30-minute Zoom/Teams interview during business hours. Both non–SA Health and SA Health staff are eligible to participate. A $50 honorarium is available for participants who are not employed by SA Health.
To review the study information and submit an expression of interest, please use the link below:
Please consider sharing this opportunity with colleagues who were involved in RSV vaccination or infant Nirsevimab delivery in 2025.
If you have any questions, please get in touch with Mark McMillan, mark.mcmillan@adelaide.edu.au Ph: 81618672
04 December 2025